Marion Subklewe

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

Michael Heuser, Sylvie Freeman, Gert J. Ossenkoppele et al. · Blood · 2021 · 666 citations · Full text

Mixed-phenotype Acute Leukemia, Pathology, Measurable Residual Disease +16

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals

Nora Philipp, Maryam Kazerani, Alyssa Nicholls et al. · Blood · 2022 · 215 citations · Full text

T-regulatory Cell, Immunology, Immunologic Mechanism +23

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Wolfgang Bethge, Peter Martus, Michael Schmitt et al. · Blood · 2022 · 210 citations · Full text

Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Marion Subklewe, Anthony S. Stein, Roland B. Walter et al. · Blood · 2019 · 86 citations

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Gloria Iacoboni, Kai Rejeski, Guillermo Villacampa et al. · Blood Advances · 2022 · 77 citations · Full text